Eidos Therapeutics Email Format
Biotechnology ResearchCalifornia, United States51-200 Employees
Eidos Therapeutics is a biotechnology company focused on developing AG10 as a targeted treatment for transthyretin amyloidosis. The program seeks to improve patient outcomes by offering a safe, effective therapy in collaboration with patients and physicians. The company was launched in 2016 after years of research supported by Stanford's SPARK program and is led by a team of experienced biotechnology executives. Headquartered in San Francisco, California, it operates as a subsidiary of BridgeBio Pharma following a merger in early 2021. Within the biotechnology research field, the organization concentrates on therapies for transthyretin amyloidosis and aims to advance AG10 toward regulatory approval.